Oncolys BioPharma Inc. announced that it has received a notice from Transposon Therapeutics Inc. ("Transposon"), licensee of OBP-601 (censavudine, TPN-101), that enrollment has been completed in the Phase IIa, double-blind, placebo-controlled study of OBP-601 in patients with Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Degeneration (FTD) who have the C9ORF72 repeat expansion mutation. In addition, Transposon has completed enrollment in a Phase IIa, double-blind, placebo-controlled study of TPN-101 in patients with Progressive Supranuclear Palsy (PSP) as well as opened enrollmen t in a Phase IIa, Open Label study of TPN-101 in patients with Aicardi-Goutières Syndrome (AGS).